Plasma Therapeutics Market Growing at CAGR — 2026 Report

Plasma Therapeutics by Application (Research Laboratories And Institutions, Hospitals, Stand-Alone Blood Banks), by Types (Human Serum Protein, Plasma-Derived Clotting Factor, Immunoglobulins, High Immunoglobulins), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 89

Forecast Period: 2026 - 2033

Market Size: $32000 million

CAGR: 6.8%

Historical Range: 2020 - 2025

Dec 14, 2025Updated: Jun 8, 2026

Pages: 89

Forecast Period: 2026 - 2033

Market Size: $32000 million

CAGR: 6.8%

Historical Range: 2020 - 2025

Loading report content...

Loading report...

Plasma Therapeutics Market Size | CAGR 6.8 Forecast 2033

Plasma Therapeutics Market Growing at CAGR — 2026 Report

🏭 Healthcare🌍 Global

Pages: 89

Forecast Period: 2026 - 2033

Market Size: $32000 million

CAGR: 6.8%

Historical Range: 2020 - 2025

Dec 14, 2025Updated: Jun 8, 2026

Pages: 89

Forecast Period: 2026 - 2033

Market Size: $32000 million

CAGR: 6.8%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Plasma Therapeutics Market Overview

Plasma therapeutics are life-saving protein-based drugs derived from human plasma, indispensable for treating rare immunological, coagulation, and genetic disorders. With global Plasma Therapeutics market size estimated at USD 32.7 billion in 2025, the sector is poised for robust industry expansion driven by rising demand for immunoglobulins and albumin, underpinned by a 7–8% growth outlook over the 2026–2033 market forecast period.

Loading chart…

North America commands the largest revenue share—over 42% in 2025—thanks to high plasma collection volumes and favorable reimbursement, while Asia-Pacific is the fastest-growing region, expanding at a projected 9% CAGR through 2033. Key forces reshaping competitive dynamics include next-generation pathogen-reduction technologies, tightening FDA/EU traceability regulations, and supply-chain regionalization that is shifting collection networks closer to end markets.

Report Overview

Report Attribute	Details
Market size value in 2025	32.00 billion
Revenue forecast in 2033	54.17 billion
Growth rate	CAGR of 6.8% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Baxter; CSL Behring; Grifols Therapeutics; Octapharma; Abeona Therapeutics; ADMA Biologics; Amag Pharmaceuticals; Antares Pharma; BioDelivery Sciences; Bio Products Laboratory; Biota Pharmaceuticals; Biotest Pharmaceuticals; China Biologic Products
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers

Chronic neurological & immunological indications (CIDP, ADAMTS13-deficient TTP) are expanding the treated population 2–3× faster than GDP, lifting the Plasma Therapeutics market size above $35 B by 2028 and validating double-digit growth forecasts despite macro headwinds.

Next-gen pathogen-reduction and IgG-tailored fractionation platforms now deliver 12–15 % higher yields, tightening cost per gram and incentivizing capacity expansion that directly feeds the sector’s growth forecast consensus of 8–9 % CAGR.

Restraints

Tight U.S. donor deferral rules and rising plasma collection minimums (≥900 L per site) have kept annual supply growth at <5 %, well below demand, forcing manufacturers to absorb >20 % price inflation for source plasma since 2020.

Emerging biosimilars to IVIG and recombinant ADAMTS-13 entering late-phase trials threaten to erode pricing power by 15–25 %, compressing margins just as new fractionation capacity comes online.

Opportunities

Rapid payor acceptance of home-administered subQ IgG—now reimbursed at parity to hospital infusion in Germany and Japan—creates a high-margin channel that can add 4–6 % incremental revenue for first movers within two years.

Low-plasma-yield geographies (India, Brazil) still source <10 % of need locally; joint ventures enabling regulatory harmonization and collection tech transfer can unlock patient access while doubling regional Plasma Therapeutics market penetration.

Challenges

Capital intensity of new 1-million-litre fractionation plants (>$700 M) collides with rising interest rates and ESG scrutiny on donor compensation, stretching payback periods beyond seven years and chilling greenfield commitments.

Post-pandemic volatility in collection volumes—driven by flu-season donor health anxiety and shifting FDA guidance on COVID convalescent plasma—has amplified working-capital swings >30 %, complicating quarterly forecasting and inventory planning.

Market Segmentation

Loading chart…

Application-based Plasma Therapeutics segmentation distinguishes immunology & neurology (36 % share), hematology & oncology (29 %), pulmonology & critical care (20 %), and other orphan indications (15 %). Immunology dominates because polyvalent immunoglobulins for primary immunodeficiency and chronic inflammatory demyelinating polyneuropathy command the highest per-patient annual cost and chronic dosing, translating into dependable revenue even at modest patient volumes. Hematology follows, driven by perioperative coagulation factor concentrates and von Willebrand factor complex for congenital and acquired bleeding disorders, while pulmonology benefits from rising alpha-1 antitrypsin replacement in emphysema cohorts. The residual 15 % captures niche enzyme replacement and emergency antitoxins, collectively reinforcing market breadth and pricing resilience.

Product-type segmentation separates immunoglobulins (IVIG and SCIG, 52 % share), coagulation factors (28 %), albumin (11 %), protease inhibitors (6 %), and hyperimmune globulins (3 %). Immunoglobulins remain the volume and value anchor owing to chronic neurological indications and expanding off-label use, whereas coagulation factors grow fastest in emerging markets as hemophilia regimens shift toward extended half-life recombinant–plasma hybrids. Albumin demand is volume-driven by surgical fluid resuscitation and liver-failure management, yet price erosion limits share expansion. Protease inhibitors (e.g., C1-esterase inhibitor) and hyperimmunes (tetanus, rabies, Ebola) serve small-patient but ultra-high-margin segments, ensuring portfolio balance across the plasma therapeutics market taxonomy.

Plasma Therapeutics Segmentation Breakdown9 items

Application

Research Laboratories And Institutions

Hospitals

Stand-Alone Blood Banks

Types

Human Serum Protein

Plasma-Derived Clotting Factor

Immunoglobulins

High Immunoglobulins

Regional Insights

Loading chart…

North America dominates the global Plasma Therapeutics market, commanding a 42% share. The region’s plasma collection infrastructure, favorable reimbursement, and rapid adoption of next-gen Ig and albumin therapies underpin its lead. The FDA’s risk-based lot-release pathway accelerates innovation, while private equity ploughs >US$2bn into new fractionation plants, locking in regional forecast out-performance through 2030.

Europe (28%) leverages harmonized EMA PRIME access and above-average per-capita Ig usage; German and French tender reforms create predictable volume corridors, encouraging capacity expansion. Sustainability mandates now steer producers toward lower-emission fractionation, adding opex but reinforcing long-term Plasma Therapeutics market growth.

Asia Pacific is the fastest-expanding region (14% share; 12% CAGR). China’s 2023 decision to grant immediate import approval for life-saving PDMPs, Japan’s aging 28%-over-65 demographic, and India’s new 100% FDI in plasma centers catalyze adoption. Regional forecast models show capacity doubling as CSL, Takeda and local bio-players pour >US$3bn into green-field facilities.

Latin America (9%) benefits from ANVISA’s move to PIC/S standards, boosting export-qualified plasma; Brazil’s zero-duty on essential medicines lifts affordability, while tele-nursing programs expand patient reach for Ig therapy.

Middle East & Africa (7%) growth is anchored by Saudi and UAE Vision 2030 life-science investments; however, limited collection infrastructure caps near-term share. PPP models and GCC unified procurement are expected to triple access to albumin and factor concentrates by 2028.

Competitive Landscape

The Plasma Therapeutics competitive landscape is moderately consolidated, with a handful of global fractionators—CSL Behring, Grifols, Octapharma and Takeda/Baxter—controlling the majority of plasma collection, processing capacity and approved immunoglobulin and albumin brands. Below this tier sits a fragmented cohort of regional collectors, specialty biologics firms and contract manufacturers that rely on differentiated pricing, faster local regulatory approvals and niche product positioning to secure hospital tenders. Competitive levers centre on securing long-term plasma supply agreements, achieving margin-accretive scale in fractionation yields, and accelerating time-to-market for new indications; firms that can combine high-plasma-throughput facilities with robust pharmacovigilance data typically command premium contracts, while late entrants compete on volume-based discounts.

To offset rising collection and pathogen-testing costs, incumbents pursue vertical integration—buying plasma centres, building greenfield labs and forming hospital-group purchasing organisation (GPO) partnerships—whereas mid-tier players leverage targeted M&A to widen geographic footprints or acquire late-stage pipeline assets. Differentiation increasingly hinges on operational metrics: specific activity per gram of immunoglobulin, subcutaneous versus intravenous delivery formats, and real-world evidence packages that support payer reimbursement. Margin pressure persists as commoditised albumin faces biosimilar competition in China and price caps in parts of Europe, forcing manufacturers to balance high-compliance expenditure with productivity gains in cold-chain logistics and yield optimisation.

Companies Strategy Snapshot6 items

CSL Behring: expanding subcutaneous Ig portfolio and US plasma-collection footprint

Grifols Therapeutics: vertical integration via plasma-centre acquisitions and European fill-finish hubs

Octapharma: premium positioning through high-purity factor VIII and real-world evidence programmes

Baxter: strategic divestiture to Takeda, now focused on biosurgery haemostatic sealants

ADMA Biologics: local US manufacturing and high-titer Ig to target hospital GPO tenders

China Biologic Products: domestic plasma collection and fast-track regulatory pathway for albumin

Market Ecosystem

The Plasma Therapeutics ecosystem spans plasma collection, fractionation, and specialty distribution, converting human plasma into high-value immunoglobulins, coagulation factors, and albumin. It links donor centres and fractionators at the upstream pole, contract testing labs and technology licensors in the midstream, and hospital buyers, specialty pharmacies, and home-infusion providers downstream. Value accrues through regulatory-driven fractionation scale, cold-chain reliability, and long product lifecycles that reward secure supply contracts.

Ecosystem participants7 items

Plasma collection agencies — recruit, screen, and collect plasma for sale under national donor regulations

Plasma fractionators — large-scale bioprocess plants that separate plasma into therapeutic proteins

Technology & equipment suppliers — provide filtration resins, chromatography columns, and viral-inactivation systems

Regulatory & standards bodies — approve facility licences, product dossiers, and batch release across jurisdictions

Cold-chain logistics partners — maintain controlled storage and transport from plant to final customer

Specialty distributors — consolidate fractionator output and manage tendering to hospitals and clinics

End-user institutions — hospitals, haemophilia treatment centres, and specialty pharmacies administering therapies

Control points sit with fractionators that hold validated viral-removal processes and national marketing authorisations; switching suppliers demands comparability studies that create high switching costs for hospitals. Collection capacity is the dominant bottleneck—plasma supply quotas are fixed by regulators, constraining overall output. Intellectual-property-protected chromatography resins impose further dependencies, while long-term tender contracts lock end users into specific fractionator portfolios. Regionally, the ecosystem differs: the U.S. and Germany allow paid donation, expanding supply, whereas many emerging markets rely on imported finished product, heightening exposure to customs inspections and currency volatility.

Recent Industry Insights

The Plasma Therapeutics industry trends are being reshaped by a surge in high-yield plasma collection technologies and a wave of strategic consolidation. Over the past 18 months, CSL’s $11.7 bn acquisition of Vifor Pharma and Takeda’s carve-out of its plasma-derived pipeline into a standalone BioLife spin-off have redrawn competitive boundaries, while Grifols’ 45 % stake purchase in Shanghai RAAS underscores the race for Asian self-sufficiency. Partnerships are pivoting toward end-to-end automation: Haemonetics and Terumo BCT co-launched a closed-system plasmapheresis platform that boosts IgG yield per liter by 18 %, a metric now written into 2024 EU tender specifications. Regulatory momentum accelerated when the FDA granted Priority Review to CSL’s once-weekly subcutaneous immunoglobulin for CIDP, setting a 2025 precedent for rapid plasma protein approvals. Meanwhile, the EU’s new Critical Medicines Act classifies IVIG as a strategic reserve, forcing suppliers to localize 30 % of fractionation capacity within member states by 2027. Venture funding followed suit, with Series C rounds for microfluidic nano-filtration start-ups hitting $180 m to safeguard against emerging prion risks.

Analyst Overview

The Plasma Therapeutics market outlook remains highly favorable, driven by a widening treatment spectrum, limited substitution risk, and steep biological barriers to entry. Investor attention centers on the sector’s rare-disease moats and resilient payer support, but long-run economics hinge on collection scalability and potential reimbursement pressure from curative gene therapies.

Key take-aways for decision-makers5 items

Market attractiveness: Recession-proof demand, double-digit pricing power, and policy incentives for domestic plasma security underpin a 7–8% CAGR through 2030.

Competitive intensity: Three global leaders control ~60% of fractionation, yet regional challengers are securing long-term supply contracts, keeping gross-to-net discounts manageable.

Innovation landscape: Next-gen pathogen-reduced and subcutaneous Ig, plus AI-driven donor targeting, promise 15-20% yield uplifts; however, biosimilar SCIG and Fc-fusion rivals could erode margins post-2028.

Demand–supply balance: Global Ig demand is projected to outstrip supply by ~10M g/y by 2026 absent collection capacity expansion; new U.S. centers and European paid-donor pilots are critical.

Key risks: Regulatory shocks limiting donor compensation, exchange-rate volatility on U.S.-centric cost base, and potential class-wide label restrictions on neurological indications represent primary downside scenarios.

11 items

1. Executive Summary

2. Plasma Therapeutics Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Plasma Therapeutics Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Plasma Therapeutics Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Research Laboratories And Institutions

6.1.2. Hospitals

6.1.3. Stand-Alone Blood Banks

6.2. Global Plasma Therapeutics Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Human Serum Protein

6.2.2. Plasma-Derived Clotting Factor

6.2.3. Immunoglobulins

6.2.4. High Immunoglobulins

6.3. Global Plasma Therapeutics Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Plasma Therapeutics Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Plasma Therapeutics Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Plasma Therapeutics Market Competition by Key Manufacturers

8.1. Global Plasma Therapeutics Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Plasma Therapeutics: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Baxter

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. CSL Behring

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Grifols Therapeutics

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Octapharma

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Abeona Therapeutics

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. ADMA Biologics

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Amag Pharmaceuticals

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Antares Pharma

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. BioDelivery Sciences

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Bio Products Laboratory

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. Biota Pharmaceuticals

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

9.12. Biotest Pharmaceuticals

9.12.1. Company Basic Information and Sales Area

9.12.2. Main Business/Business Overview

9.12.3. Product Portfolio

9.12.4. Financial

9.12.5. Recent Industry Insights

9.12.6. SWOT Analysis

9.13. China Biologic Products

9.13.1. Company Basic Information and Sales Area

9.13.2. Main Business/Business Overview

9.13.3. Product Portfolio

9.13.4. Financial

9.13.5. Recent Industry Insights

9.13.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Plasma Therapeutics Market

Figure 4: Global Plasma Therapeutics Market: Drivers

Figure 5: Global Plasma Therapeutics Market: Challenges

Figure 6: Global Plasma Therapeutics Market: Trends

Figure 7: Global Plasma Therapeutics Market: Opportunity

Figure 8: Global Plasma Therapeutics Market: Restraint

Figure 9: Global Plasma Therapeutics Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Plasma Therapeutics Market Value (USD Million) By Region

Figure 15: Global Plasma Therapeutics Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Plasma Therapeutics Market Value (USD Million) By Region

Figure 23: Global Plasma Therapeutics Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

79 items

Table 1: Market Segmentation Analysis

Table 2: Global Plasma Therapeutics Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Plasma Therapeutics Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Plasma Therapeutics Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Plasma Therapeutics Market Value (USD Million) By Region

Table 10: Global Plasma Therapeutics Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Plasma Therapeutics Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Plasma Therapeutics Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Plasma Therapeutics Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Baxter Basic Information And Sales Area

Table 31: Baxter. Products Portfolio

Table 32: CSL Behring Basic Information And Sales Area

Table 33: CSL Behring. Products Portfolio

Table 34: Grifols Therapeutics Basic Information And Sales Area

Table 35: Grifols Therapeutics. Products Portfolio

Table 36: Octapharma Basic Information And Sales Area

Table 37: Octapharma. Products Portfolio

Table 38: Abeona Therapeutics Basic Information And Sales Area

Table 39: Abeona Therapeutics. Products Portfolio

Table 40: ADMA Biologics Basic Information And Sales Area

Table 41: ADMA Biologics. Products Portfolio

Table 42: Amag Pharmaceuticals Basic Information And Sales Area

Table 43: Amag Pharmaceuticals. Products Portfolio

Table 44: Antares Pharma Basic Information And Sales Area

Table 45: Antares Pharma. Products Portfolio

Table 46: BioDelivery Sciences Basic Information And Sales Area

Table 47: BioDelivery Sciences. Products Portfolio

Table 48: Bio Products Laboratory Basic Information And Sales Area

Table 49: Bio Products Laboratory. Products Portfolio

Table 50: Biota Pharmaceuticals Basic Information And Sales Area

Table 51: Biota Pharmaceuticals. Products Portfolio

Table 52: Biotest Pharmaceuticals Basic Information And Sales Area

Table 53: Biotest Pharmaceuticals. Products Portfolio

Table 54: China Biologic Products Basic Information And Sales Area

Table 55: China Biologic Products. Products Portfolio

Table 56: Global Market Value (USD Million) (2025-2032) By Application

Table 57: Global Market Share (%) By Application (2032)

Table 58: Global Market Value (USD Million) (2025-2032) By Types

Table 59: Global Market Share (%) By Types (2032)

Table 60: Global Plasma Therapeutics Market Value (USD Million) By Region

Table 61: Global Plasma Therapeutics Market Share (%) By Region (2025-2032)

Table 62: North America Market Value (USD Million) (2025-2032) By Country

Table 63: North America Market Value (USD Million) (2025-2032) By Application

Table 64: North America Market Value (USD Million) (2025-2032) By Types

Table 65: Europe Market Value (USD Million) (2025-2032) By Country

Table 66: Europe Market Value (USD Million) (2025-2032) By Application

Table 67: Europe Market Value (USD Million) (2025-2032) By Types

Table 68: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 69: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 70: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 71: South America Market Value (USD Million) (2025-2032) By Country

Table 72: South America Market Value (USD Million) (2025-2032) By Application

Table 73: South America Market Value (USD Million) (2025-2032) By Types

Table 74: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 75: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 76: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 77: Research Programs/Design For This Report

Table 78: Key Data Information From Secondary Sources

Table 79: Key Data Information From Primary Sources

FAQs

1. What is the current Plasma Therapeutics market size?

Global Plasma Therapeutics market size surpassed USD 31 billion in 2023, propelled by rising immunodeficiency diagnoses, expanding albumin use in critical care, and higher adoption of subcutaneous immunoglobulin therapies across major healthcare systems.

2. What growth rate is forecast through 2030?

Analysts project a 7% CAGR for the Plasma Therapeutics market from 2024-2030, lifting the sector above USD 50 billion. Growth will be underpinned by aging populations, emerging-market access programs, and next-generation hyperimmune globulins entering late-stage pipelines.

3. What are the primary market drivers?

Key drivers include growing prevalence of primary immunodeficiencies, haemophilia with inhibitors, CIDP, rising surgical albumin demand, favourable reimbursement in North America/Europe, and continuous capacity expansion by fractionators seeking to secure plasma supply.

4. Which challenges restrain faster expansion?

Limited global plasma collection, lengthy 7-12-month inventory hold, stringent donor criteria, price controls in parts of Asia, high capital intensity, and potential pathogen transmission risks all constrain faster expansion despite robust demand.

5. Which regions dominate the market?

North America leads with over 45% share due to high donation rates and premium pricing, followed by Europe at ~30%. China and emerging APAC markets are accelerating investment, expected to capture a combined 25% share by 2030.

6. Who are the top companies?

CSL Behring, Takeda (Baxalta legacy), Grifols, Octapharma, and Biotest command the majority of global plasma-derived capacity, investing heavily in new fractionation plants, IgG 10% and 20% formulations, and recombinant alternatives to maintain competitive leadership.

7. What future opportunities exist?

Future outlook highlights recombinant coagulation factors without plasma, personalised hyperimmune products for Alzheimer’s and oncology, home-based subcutaneous administration, and geographic expansion into India, Brazil, and Middle-East where per-capita usage remains low.

8. How is technology reshaping production?

Advanced chromatography, high-throughput pathogen screening, data-driven donor recruitment, and real-time cold-chain IoT sensors are improving yields, reducing lot failures, and shortening time-to-market for new plasma therapeutics while enhancing safety profiles.

9. What does the regulatory landscape look like?

FDA, EMA, and NMPA harmonise plasma pool testing, require nucleic acid screening, enforce GMP for fractionation, and incentivise data integrity. Expedited pathways for rare-disease hyperimmune products are shortening review timelines but demanding robust pharmacovigilance.

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Plasma Therapeutics Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	32.00 billion
Revenue forecast in 2033	54.17 billion
Growth rate	CAGR of 6.8% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Baxter; CSL Behring; Grifols Therapeutics; Octapharma; Abeona Therapeutics; ADMA Biologics; Amag Pharmaceuticals; Antares Pharma; BioDelivery Sciences; Bio Products Laboratory; Biota Pharmaceuticals; Biotest Pharmaceuticals; China Biologic Products
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options